ETH Ventures

ETH Ventures operates as the venture and entrepreneurship arm of ETH Zurich, channeling research and deep tech founders out of one of the world’s strongest technical universities into the early-stage venture market. The AI Launchpad program sits at the center of the healthcare-relevant activity, supporting computational health research and AI-applied life sciences projects through to commercialization. The firm’s healthcare interest concentrates on AI/ML applications and life sciences tools.

The thesis is grounded in the proposition that ETH Zurich produces genuinely world-class technical research and that the bottleneck to commercialization is operational rather than scientific. ETH Ventures provides the structural support, modest capital, and ecosystem connections that allow research-stage founders to make the transition into venture-backable companies. Healthcare investments under this thesis are characterized by deep technical foundations, often emerging directly from ETH research groups, with a strong bias toward computational and AI-driven approaches over traditional wet-lab biotech.

The firm writes checks generally below $250k at the pre-seed and seed stages, which is calibrated to the academic spinout context rather than to fully formed venture rounds. The check size functions as a bridge between research grants and the first institutional seed round from a traditional venture firm. Geographically, the focus is Switzerland with strong density in the ETH Zurich ecosystem, though companies with ETH-affiliated founders operating internationally remain in scope. The accelerator-investor model means founders typically engage with the program before any capital decision, which provides time for both sides to develop conviction and for the company to reach a state where outside venture capital becomes appropriate.

The team operates within the broader ETH institutional context, with access to research labs, technical advisory benches, and the alumni network across Europe and globally. For healthcare AI founders, that institutional access can be more valuable than the dollar amount of the initial check, particularly when the technology requires research-grade validation or specialized infrastructure.

In working with companies, ETH Ventures is most useful for technical advisory, research collaboration, and bridging founders into the broader Swiss and European venture ecosystem. The firm has connections into seed and Series A leads in Zurich, Geneva, Berlin, London, Paris, and the US that can lead subsequent rounds when companies graduate from the program. Board involvement is structured around the program’s framework rather than traditional venture board mechanics. For healthcare founders, the fit is strongest for those with research-driven companies emerging from the ETH ecosystem or those whose technology requires the kind of technical depth that the ETH network provides. The fit is weaker for purely commercial digital health businesses where the moat is distribution or brand. Founders considering ETH Ventures should plan to engage with the program structure, leverage the institutional network, and treat the initial check as a stepping stone to a larger seed round rather than as the primary financing event.